Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 9/20 | 0.58 |
| ▸ | PSEN2 | P49810 | 9/20 | 0.58 |
| ▸ | APH1B | Q8WW43 | 9/20 | 0.58 |
| ▸ | NCSTN | Q92542 | 9/20 | 0.58 |
| ▸ | APH1A | Q96BI3 | 9/20 | 0.58 |
| ▸ | PSENEN | Q9NZ42 | 9/20 | 0.58 |
| ▸ | NOTCH1 | P46531 | 3/20 | 0.58 |
| ▸ | RBPJ | Q06330 | 2/20 | 0.58 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.57 |
| ▸ | CCKBR | P32239 | 5/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13914014 | 0.98 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4159109 | 0.94 | PSEN1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4160420 | 0.93 | NOTCH1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13904662 | 0.93 | NOTCH1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4144414 | 0.93 | NOTCH1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4153312 | 0.93 | NOTCH1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13914172 | 0.92 | NOTCH1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4168240 | 0.92 | NOTCH1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4151511 | 0.92 | NOTCH1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13904790 | 0.91 | NOTCH1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | disclosed |
| US-7354914-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | APH1A, APH1B, APP | PSEN1 7/4885PSEN2 8/4885APH1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.